Back to Search
Start Over
Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse(R) in Greater China with Baylor BioSciences
- Source :
- GlobeNewswire. January 5, 2023
- Publication Year :
- 2023
-
Abstract
- WARREN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ('Bellerophon' or the 'Company'), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.732267147